{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:41:30Z","timestamp":1761237690310},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,1,29]],"date-time":"2010-01-29T00:00:00Z","timestamp":1264723200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00228-009-0779-4","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T06:43:40Z","timestamp":1264661020000},"page":"369-374","source":"Crossref","is-referenced-by-count":17,"title":["Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example"],"prefix":"10.1007","volume":"66","author":[{"given":"Alain","family":"Li-Wan-Po","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Farndon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,29]]},"reference":[{"issue":"7","key":"779_CR1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMp020079","volume":"347","author":"R Schwartz","year":"2002","unstructured":"Schwartz R (2002) A molecular star in the wars against cancer. N Engl J Med 347(7):462\u2013463","journal-title":"N Engl J Med"},{"key":"779_CR2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GDvMM Demetri","year":"2002","unstructured":"Demetri GDvMM, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. A molecular star in the wars against cancer. N Engl J Med 347:472\u2013480","journal-title":"N Engl J Med"},{"issue":"4","key":"779_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(05)70097-8","volume":"6","author":"E Wardelmann","year":"2005","unstructured":"Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R et al (2005) Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6(4):249\u2013251","journal-title":"Lancet Oncol"},{"issue":"2","key":"779_CR4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2002-05-1451","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101(2):473\u2013475","journal-title":"Blood"},{"issue":"3","key":"779_CR5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","volume":"115","author":"HM Kantarjian","year":"2009","unstructured":"Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M et al (2009) Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115(3):551\u2013560","journal-title":"Cancer"},{"issue":"10","key":"779_CR6","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N et al (2009) Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154\u20132160","journal-title":"Blood"},{"issue":"12","key":"779_CR7","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12):3739\u20133745","journal-title":"Blood"},{"issue":"8","key":"779_CR8","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109(8):3496\u20133499","journal-title":"Blood"},{"issue":"6","key":"779_CR9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","volume":"65","author":"N Singh","year":"2009","unstructured":"Singh N, Kumar L, Meena R, Velpandian T (2009) Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 65(6):545\u2013549","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"779_CR10","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111(8):4022\u20134028","journal-title":"Blood"},{"issue":"11","key":"779_CR11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348(11):994\u20131004","journal-title":"N Engl J Med"},{"issue":"23","key":"779_CR12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417","journal-title":"N Engl J Med"},{"key":"779_CR13","volume-title":"Signal detection theory and psychophysics","author":"DM Green","year":"1966","unstructured":"Green DM, Swets JA (1966) Signal detection theory and psychophysics. Peninsula Publ, Los Altos"},{"issue":"6","key":"779_CR14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108(6):1809\u20131820","journal-title":"Blood"},{"issue":"14","key":"779_CR15","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","volume":"344","author":"H Joensuu","year":"2001","unstructured":"Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052\u20131056","journal-title":"N Engl J Med"},{"issue":"9","key":"779_CR16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346(9):645\u2013652","journal-title":"N Engl J Med"},{"issue":"7","key":"779_CR17","first-page":"2177","volume":"8","author":"HM Kantarjian","year":"2002","unstructured":"Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S et al (2002) Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 8(7):2177\u20132187","journal-title":"Clin Cancer Res"},{"issue":"19","key":"779_CR18","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E et al (2009) Comparison of imatinib 400\u00a0mg and 800\u00a0mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet study. Blood 113(19):4497\u20134504","journal-title":"Blood"},{"key":"779_CR19","volume-title":"Genomic medicine, vol 1","author":"Science and Technology Committee","year":"2009","unstructured":"Science and Technology Committee (2009) Genomic medicine, vol 1. House of Lords, London"},{"issue":"2","key":"779_CR20","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/107327480901600203","volume":"16","author":"MJ Mauro","year":"2009","unstructured":"Mauro MJ (2009) Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Cancer Control 16(2):108\u2013121","journal-title":"Cancer Control"},{"key":"779_CR21","unstructured":"Pollack A (2009) As pills treat cancer, insurance lags behind. New York Times 2009, April 15th:A1"},{"issue":"19","key":"779_CR22","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMp0806862","volume":"359","author":"R Steinbrook","year":"2008","unstructured":"Steinbrook R (2008) Saying no isn't NICE\u2014the travails of Britain's National Institute for Health and Clinical Excellence. N Engl J Med 359(19):1977\u20131981","journal-title":"N Engl J Med"},{"issue":"14","key":"779_CR23","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","volume":"15","author":"DH Kim","year":"2009","unstructured":"Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K et al (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15(14):4750\u20134758","journal-title":"Clin Cancer Res"},{"issue":"2","key":"779_CR24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian HM, Cortes JE (2009) Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16(2):122\u2013131","journal-title":"Cancer Control"},{"issue":"1","key":"779_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.003","volume":"274","author":"G Volpe","year":"2009","unstructured":"Volpe G, Panuzzo C, Ulisciani S, Cilloni D (2009) Imatinib resistance in CML. Cancer Lett 274(1):1\u20139","journal-title":"Cancer Lett"},{"issue":"20","key":"779_CR26","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","volume":"114","author":"RJ Garg","year":"2009","unstructured":"Garg RJ, Kantarjian H, O'Brien S, Quintas-Cardama A, Faderl S, Estrov Z et al (2009) The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 114(20):4361\u20134368","journal-title":"Blood"},{"issue":"5","key":"779_CR27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11912-009-0046-y","volume":"11","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J (2009) Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Curr Oncol Rep 11(5):337\u2013345","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"779_CR28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11523-008-0100-y","volume":"4","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Cortes J, Kantarjian H (2009) Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 4(1):3\u201310","journal-title":"Target Oncol"},{"issue":"9","key":"779_CR29","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879\u2013894","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"779_CR30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","volume":"80","author":"ER Gardner","year":"2006","unstructured":"Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G et al (2006) Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80(2):192\u2013201","journal-title":"Clin Pharmacol Ther"},{"key":"779_CR31","doi-asserted-by":"crossref","unstructured":"Li-Wan-Po A, Farndon P, Cooley C, Lithgow J (2010) When is a genetic test suitable for prime time? predicting the risk of prostate cancer as a case-example. Public Health Genomics 13:55\u201362. doi: 10.1159\/000218710","DOI":"10.1159\/000218710"},{"key":"779_CR32","doi-asserted-by":"crossref","unstructured":"Li-Wan-Po A (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. doi: 10.1111\/j.1365-2125.2009.03578.x","DOI":"10.1111\/j.1365-2125.2009.03578.x"},{"issue":"6","key":"779_CR33","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/mp9000298","volume":"6","author":"HE Meyer zu Schwabedissen","year":"2009","unstructured":"Meyer zu Schwabedissen HE, Kim RB (2009) Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol Pharm 6(6):1644\u20131661","journal-title":"Mol Pharm"},{"issue":"4","key":"779_CR34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","volume":"1","author":"TM Willson","year":"2002","unstructured":"Willson TM, Kliewer SA (2002) PXR, CAR and drug metabolism. Nat Rev Drug Discov 1(4):259\u2013266","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"779_CR35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00210-003-0815-3","volume":"369","author":"O Burk","year":"2004","unstructured":"Burk O, Wojnowski L (2004) Cytochrome P450 3A and their regulation. Naunyn Schmiedebergs Arch Pharmacol 369(1):105\u2013124","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"15","key":"779_CR36","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.1074\/jbc.M709382200","volume":"283","author":"S Takagi","year":"2008","unstructured":"Takagi S, Nakajima M, Mohri T, Yokoi T (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283(15):9674\u20139680","journal-title":"J Biol Chem"},{"issue":"8","key":"779_CR37","first-page":"2119","volume":"119","author":"PJ Mishra","year":"2009","unstructured":"Mishra PJ, Merlino G (2009) MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest 119(8):2119\u20132123","journal-title":"J Clin Invest"},{"issue":"6","key":"779_CR38","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1021\/mp900253n","volume":"6","author":"LZ Benet","year":"2009","unstructured":"Benet LZ (2009) The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6(6):1631\u20131643","journal-title":"Mol Pharm"},{"issue":"1","key":"779_CR39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","volume":"82","author":"H Gurney","year":"2007","unstructured":"Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM et al (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82(1):33\u201340","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"779_CR40","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14(21):7102\u20137109","journal-title":"Clin Cancer Res"},{"issue":"7","key":"779_CR41","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/1078-0432.CCR-0785-3","volume":"10","author":"MA Dressman","year":"2004","unstructured":"Dressman MA, Malinowski R, McLean LA, Gathmann I, Capdeville R, Hensley M et al (2004) Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571). Clin Cancer Res 10(7):2265\u20132271","journal-title":"Clin Cancer Res"},{"issue":"1 Pt 1","key":"779_CR42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-0784-3","volume":"10","author":"LA McLean","year":"2004","unstructured":"McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M (2004) Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 10(1 Pt 1):155\u2013165","journal-title":"Clin Cancer Res"},{"issue":"2","key":"779_CR43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","volume":"53","author":"AE Bolton","year":"2004","unstructured":"Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53(2):102\u2013106","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"779_CR44","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/sj.bjc.6601152","volume":"89","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C et al (2003) Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89(10):1855\u20131859","journal-title":"Br J Cancer"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0779-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0779-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0779-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:52:05Z","timestamp":1558687925000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0779-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,29]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0779-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,29]]}}}